Agenus Inc. (NASDAQ:AGEN) shares traded -0.58% lower at $1.70 on Wall Street last session.
In accordance with the data, 6 analysts cover Agenus Inc. (NASDAQ:AGEN). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $8.30 and a low of $6.00, we find $8.00. Given the previous closing price of $1.71, this indicates a potential upside of 367.84 percent. AGEN stock price is now 2.27% away from the 50-day moving average and -17.75% away from the 200-day moving average. The market capitalization of the company currently stands at $623.39M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
It has been rated a hold by 0 analysts and a buy by 5. Brokers who have rated the stock have averaged $7.66 as their price target over the next twelve months.
With the price target of $8, Robert W. Baird recently initiated with Outperform rating for Agenus Inc. (NASDAQ: AGEN).
In other news, AGENUS INC, 10% Owner bought 23,361 shares of the company’s stock on May 11. The stock was bought for $33,348 at an average price of $1.43. Upon completion of the transaction, the 10% Owner now directly owns 21,640,473 shares in the company, valued at $36.79 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 10, 10% Owner AGENUS INC bought 22,065 shares of the business’s stock. A total of $33,296 was incurred on buying the stock at an average price of $1.51. This leaves the insider owning 21,617,112 shares of the company worth $36.75 million. A total of 8.21% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AGEN stock. A new stake in Agenus Inc. shares was purchased by PROFUND ADVISORS LLC during the first quarter worth $684,000. ALLIANZ ASSET MANAGEMENT GMBH invested $328,000 in shares of AGEN during the first quarter. In the first quarter, ASSENAGON ASSET MANAGEMENT S.A. acquired a new stake in Agenus Inc. valued at approximately $294,000. AIGEN INVESTMENT MANAGEMENT, LP acquired a new stake in AGEN for approximately $149,000. MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. purchased a new stake in AGEN valued at around $141,000 in the second quarter. In total, there are 222 active investors with 59.60% ownership of the company’s stock.
During the past 12 months, Agenus Inc. has had a low of $1.28 and a high of $3.31. The fifty day moving average price for AGEN is $1.6648 and a two-hundred day moving average price translates $2.0652 for the stock.
The latest earnings results from Agenus Inc. (NASDAQ: AGEN) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.22, missing analysts’ expectations of -$0.21 by -0.01. This compares to -$0.20 EPS in the same period last year. The company reported revenue of $22.9 million for the quarter, compared to $25.94 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -11.72 percent. For the current quarter, analysts expect AGEN to generate $24.12M in revenue.
Agenus Inc.(AGEN) Company Profile
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 2 clinical trial; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; BMS-986442, a TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, it develops INCAGN1876, a GITR monospecific antibody; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
